Canaccord Maintains Hold, $23 Target on Genomic Health

Canaccord reiterates its Hold rating and $23 target on Genomic Health

as the company's DCIS test is validated at San Antonio breast cancer meeting. Canaccord says, “DCIS study met primary endpoint. The DCIS validation study demonstrated that 75% of patients have a low DCIS score and have only a 12% chance of recurrence, while high DCIS scores had a 27% likelihood of recurrence. …DCIS market estimates. With approximately 40,000 patients diagnosed with DCIS in the US each year, we estimate the opportunity at $130M.” GHDX closed at $28.47 per share on Tuesday.